▶ 調査レポート

遺伝子ベクターのグローバル市場(2022年-2031年):レンチウイルス、アデノウイルス、アデノ随伴ウイルス、プラスミドDNA、その他

• 英文タイトル:Gene Vector Market (Vector Type: Lentivirus, Adenovirus, Adeno-associated Virus (AAV), Plasmid DNA, and Others, Disease: Genetic Disorder, Cancer, Infectious Disease, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Transparency Market Researchが調査・発行した産業分析レポートです。遺伝子ベクターのグローバル市場(2022年-2031年):レンチウイルス、アデノウイルス、アデノ随伴ウイルス、プラスミドDNA、その他 / Gene Vector Market (Vector Type: Lentivirus, Adenovirus, Adeno-associated Virus (AAV), Plasmid DNA, and Others, Disease: Genetic Disorder, Cancer, Infectious Disease, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031 / MRC2304D086資料のイメージです。• レポートコード:MRC2304D086
• 出版社/出版日:Transparency Market Research / 2023年1月12日
• レポート形態:英文、PDF、190ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥869,250 (USD5,795)▷ お問い合わせ
  Multi User¥1,319,250 (USD8,795)▷ お問い合わせ
  Corporate License¥1,769,250 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Transparency Market Research社の当調査レポートでは、遺伝子ベクターの世界市場を分析し、市場実態を明らかにしています。本書は、序論、仮定&調査手法、エグゼクティブサマリー、市場概要、キーインサイト、市場分析&予測、ベクター種類別(レンチウイルス、アデノウイルス、アデノ随伴ウイルス、プラスミドDNA、その他)分析、用途別(遺伝子治療、ワクチン、その他)分析、疾患別(遺伝性疾患、がん、感染症、その他)分析、エンドユーザー別(科学研究、CRO、CDMO)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)分析、競争状況などを収録しています。また、Lonza、Merck KGaA、Oxford Biomedica、CGT Catapult、Charles River Laboratories、uniQure N.V.、FUJIFILM Diosynth Biotechnologies、Spark Therapeutics, Inc.などの企業情報を掲載しています。
・序論
・仮定&調査手法
・エグゼクティブサマリー
・市場概要
・キーインサイト
・市場分析&予測
・世界の遺伝子ベクター市場規模:ベクター種類別
- レンチウイルスの市場規模
- アデノウイルスの市場規模
- アデノ随伴ウイルスの市場規模
- プラスミドDNAの市場規模
- その他ベクター種類の市場規模
・世界の遺伝子ベクター市場規模:用途別
- 遺伝子治療における市場規模
- ワクチンにおける市場規模
- その他用途における市場規模
・世界の遺伝子ベクター市場規模:疾患別
- 遺伝性疾患における市場規模
- がんにおける市場規模
- 感染症における市場規模
- その他疾患における市場規模
・世界の遺伝子ベクター市場規模:エンドユーザー別
- CRO科学研究における市場規模
- CDMOにおける市場規模
・世界の遺伝子ベクター市場規模:地域別
- 北米の遺伝子ベクター市場規模
- ヨーロッパの遺伝子ベクター市場規模
- アジア太平洋の遺伝子ベクター市場規模
- 中南米のアルミニウムスラグ市場規模
- 中東・アフリカのアルミニウムスラグ市場規模
・競争状況

Gene Vector Market – Scope of Report
TMR’s report on the global gene vector market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global gene vector market for the period 2017–2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global gene vector market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the gene vector market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global gene vector market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global gene vector market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global gene vector market.

The report delves into the competitive landscape of the global gene vector market. Key players operating in the global gene vector market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global gene vector market profiled in this report.

RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market gene vector.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

• Industry Sources:
o WorldWideScience.org
o Elsevier, Inc.
o National Institutes of Health (NIH)
o PubMed
o NCBI
o Department of Health Care Service
• Trade Data Sources
o Trade Map
o UN Comtrade
o Trade Atlas
• Company Information
o OneSource Business Browser
o Hoover’s
o Factiva
o Bloomberg
• Mergers & Acquisitions
o Thomson Mergers & Acquisitions
o MergerStat
o Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:

Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

レポート目次

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Gene Vector Market
4. Market Overview
    4.1. Introduction
        4.1.1. Definition
        4.1.2. Industry Evolution/Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Gene Vector Market Analysis and Forecasts, 2017 – 2031
        4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
    5.1. Technological Advancements
    5.2. Major Research Institutes Involved
    5.3. Disease Prevalence & Incidence Rate globally with key countries
    5.4. COVID-19 Pandemic Impact on Industry
6. Global Gene Vector Market Analysis and Forecast, by Vector Type
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast, by Vector Type, 2017 – 2031
        6.3.1. Lentivirus
        6.3.2. Adenovirus
        6.3.3. Adeno-associated Virus (AAV)
        6.3.4. Plasmid DNA
        6.3.5. Others
    6.4. Market Attractiveness, by Vector Type
7. Global Gene Vector Market Analysis and Forecast, by Application
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Application, 2017 – 2031
        7.3.1. Gene Therapy
        7.3.2. Vaccinology
        7.3.3. Others
    7.4. Market Attractiveness, by Application
8. Global Gene Vector Market Analysis and Forecast, by Disease
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast, by Disease, 2017 – 2031
        8.3.1. Genetic Disorder
        8.3.2. Cancer
        8.3.3. Infectious Disease
        8.3.4. Others
    8.4. Market Attractiveness, by Disease
9. Global Gene Vector Market Analysis and Forecast, by End-user
    9.1. Introduction & Definition
    9.2. Key Findings / Developments
    9.3. Market Value Forecast, by End-user, 2017 – 2031
        9.3.1. Scientific Research
        9.3.2. CRO
        9.3.3. CDMO
        9.3.4. Others (Pharmaceutical, Biotechnology Companies)
    9.4. Market Attractiveness, by End-user
10. Global Gene Vector Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness, by Country/Region
11. North America Gene Vector Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Vector Type, 2017 – 2031
        11.2.1. Lentivirus
        11.2.2. Adenovirus
        11.2.3. Adeno-associated Virus (AAV)
        11.2.4. Plasmid DNA
        11.2.5. Others
    11.3. Market Value Forecast, by Application, 2017 – 2031
        11.3.1. Gene Therapy
        11.3.2. Vaccinology
        11.3.3. Others
    11.4. Market Value Forecast, by Disease, 2017 – 2031
        11.4.1. Genetic Disorder
        11.4.2. Cancer
        11.4.3. Infectious Disease
        11.4.4. Others
    11.5. Market Value Forecast, by End-user, 2017 – 2031
        11.5.1. Scientific Research
        11.5.2. CRO
        11.5.3. CDMO
        11.5.4. Others (Pharmaceutical, Biotechnology Companies)
    11.6. Market Value Forecast, by Country, 2017 – 2031
        11.6.1. U.S.
        11.6.2. Canada
    11.7. Market Attractiveness Analysis
        11.7.1. By Vector Type
        11.7.2. By Application
        11.7.3. By Disease
        11.7.4. By End-user
        11.7.5. By Country
12. Europe Gene Vector Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Vector Type, 2017 – 2031
        12.2.1. Lentivirus
        12.2.2. Adenovirus
        12.2.3. Adeno-associated Virus (AAV)
        12.2.4. Plasmid DNA
        12.2.5. Others
    12.3. Market Value Forecast, by Application, 2017 – 2031
        12.3.1. Gene Therapy
        12.3.2. Vaccinology
        12.3.3. Others
    12.4. Market Value Forecast, by Disease, 2017 – 2031
        12.4.1. Genetic Disorder
        12.4.2. Cancer
        12.4.3. Infectious Disease
        12.4.4. Others
    12.5. Market Value Forecast, by End-user, 2017 – 2031
        12.5.1. Scientific Research
        12.5.2. CRO
        12.5.3. CDMO
        12.5.4. Others (Pharmaceutical, Biotechnology Companies)
    12.6. Market Value Forecast, by Country, 2017 – 2031
        12.6.1. Germany
        12.6.2. U.K.
        12.6.3. France
        12.6.4. Spain
        12.6.5. Italy
        12.6.6. Rest of Europe
    12.7. Market Attractiveness Analysis
        12.7.1. By Vector Type
        12.7.2. By Application
        12.7.3. By Disease
        12.7.4. By End-user
        12.7.5. By Country
13. Asia Pacific Gene Vector Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Vector Type, 2017 – 2031
        13.2.1. Lentivirus
        13.2.2. Adenovirus
        13.2.3. Adeno-associated Virus (AAV)
        13.2.4. Plasmid DNA
        13.2.5. Others
    13.3. Market Value Forecast, by Application, 2017 – 2031
        13.3.1. Gene Therapy
        13.3.2. Vaccinology
        13.3.3. Others
    13.4. Market Value Forecast, by Disease, 2017 – 2031
        13.4.1. Genetic Disorder
        13.4.2. Cancer
        13.4.3. Infectious Disease
        13.4.4. Others
    13.5. Market Value Forecast, by End-user, 2017 – 2031
        13.5.1. Scientific Research
        13.5.2. CRO
        13.5.3. CDMO
        13.5.4. Others (Pharmaceutical, Biotechnology Companies)
    13.6. Market Value Forecast, by Country, 2017 – 2031
        13.6.1. China
        13.6.2. Japan
        13.6.3. India
        13.6.4. Australia & New Zealand
        13.6.5. Rest of Asia Pacific
    13.7. Market Attractiveness Analysis
        13.7.1. By Vector Type
        13.7.2. By Application
        13.7.3. By Disease
        13.7.4. By End-user
        13.7.5. By Country
14. Latin America Gene Vector Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Vector Type, 2017 – 2031
        14.2.1. Lentivirus
        14.2.2. Adenovirus
        14.2.3. Adeno-associated Virus (AAV)
        14.2.4. Plasmid DNA
        14.2.5. Others
    14.3. Market Value Forecast, by Application, 2017 – 2031
        14.3.1. Gene Therapy
        14.3.2. Vaccinology
        14.3.3. Others
    14.4. Market Value Forecast, by Disease, 2017 – 2031
        14.4.1. Genetic Disorder
        14.4.2. Cancer
        14.4.3. Infectious Disease
        14.4.4. Others
    14.5. Market Value Forecast, by End-user, 2017 – 2031
        14.5.1. Scientific Research
        14.5.2. CRO
        14.5.3. CDMO
        14.5.4. Others (Pharmaceutical, Biotechnology Companies)
    14.6. Market Value Forecast, by Country, 2017 – 2031
        14.6.1. Brazil
        14.6.2. Mexico
        14.6.3. Rest of Latin America
    14.7. Market Attractiveness Analysis
        14.7.1. By Vector Type
        14.7.2. By Application
        14.7.3. By Disease
        14.7.4. By End-user
        14.7.5. By Country
15. Middle East & Africa Gene Vector Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Vector Type, 2017 – 2031
        15.2.1. Lentivirus
        15.2.2. Adenovirus
        15.2.3. Adeno-associated Virus (AAV)
        15.2.4. Plasmid DNA
        15.2.5. Others
    15.3. Market Value Forecast, by Application, 2017 – 2031
        15.3.1. Gene Therapy
        15.3.2. Vaccinology
        15.3.3. Others
    15.4. Market Value Forecast, by Disease, 2017 – 2031
        15.4.1. Genetic Disorder
        15.4.2. Cancer
        15.4.3. Infectious Disease
        15.4.4. Others
    15.5. Market Value Forecast, by End-user, 2017 – 2031
        15.5.1. Scientific Research
        15.5.2. CRO
        15.5.3. CDMO
        15.5.4. Others (Pharmaceutical, Biotechnology Companies)
    15.6. Market Value Forecast, by Country, 2017 – 2031
        15.6.1. GCC Countries
        15.6.2. South Africa
        15.6.3. Rest of Middle East & Africa
    15.7. Market Attractiveness Analysis
        15.7.1. By Vector Type
        15.7.2. By Application
        15.7.3. By Disease
        15.7.4. By End-user
        15.7.5. By Country
16. Competition Landscape
    16.1. Market Player – Competition Matrix (By Tier and Size of companies)
    16.2. Market Share Analysis By Company (2021)
    16.3. Company Profiles
        16.3.1. Lonza
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Product Portfolio
            16.3.1.3. Financial Overview
            16.3.1.4. SWOT Analysis
            16.3.1.5. Strategic Overview
        16.3.2. Merck KGaA
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Product Portfolio
            16.3.2.3. Financial Overview
            16.3.2.4. SWOT Analysis
            16.3.2.5. Strategic Overview
        16.3.3. Oxford Biomedica
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Product Portfolio
            16.3.3.3. Financial Overview
            16.3.3.4. SWOT Analysis
            16.3.3.5. Strategic Overview
        16.3.4. CGT Catapult
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Product Portfolio
            16.3.4.3. Financial Overview
            16.3.4.4. SWOT Analysis
            16.3.4.5. Strategic Overview
        16.3.5. Charles River Laboratories
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Product Portfolio
            16.3.5.3. Financial Overview
            16.3.5.4. SWOT Analysis
            16.3.5.5. Strategic Overview
        16.3.6. uniQure N.V.
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Product Portfolio
            16.3.6.3. Financial Overview
            16.3.6.4. SWOT Analysis
            16.3.6.5. Strategic Overview
        16.3.7. FUJIFILM Diosynth Biotechnologies
            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.7.2. Product Portfolio
            16.3.7.3. Financial Overview
            16.3.7.4. SWOT Analysis
            16.3.7.5. Strategic Overview
        16.3.8. Spark Therapeutics, Inc.
            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.8.2. Product Portfolio
            16.3.8.3. Financial Overview
            16.3.8.4. SWOT Analysis
            16.3.8.5. Strategic Overview
        16.3.9. Other Prominent Players